Introduction
The ecotropic viral integration site-1 (Evi-1) gene is a member of the SET/PR domain family of transcription factors (Fears et al., 1996; Nitta et al., 2005) . It has been shown to interact with several transcriptional regulators like Smad3, CtBP, and PU.1, to mediate transcription (Kurokawa et al., 1998; Izutsu et al., 2001; LaricchiaRobbio et al., 2009) . The gene targeting studies in mice revealed that Evi-1 is essential for the proliferation and maintenance of hematopoietic stem cells (HSCs) both during embryogenesis and in the adult (Yuasa et al., 2005; Goyama et al., 2008) . Evi-1 regulates HSC proliferation through Gata2 upregulation and repression of TGF-b signaling in the early hematopoietic development (Yuasa et al., 2005; Sato et al., 2008) . In humans, aberrant expression of Evi-1 oncoprotein confers a poor prognosis in hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome, particularly in patients with rearrangements on chromosome 3q26, in which Evi-1 is mapped (Pintado et al., 1985; Suzukawa et al., 1994; Ogawa et al., 1996) . Overexpression of Evi-1 occurs with high frequency in a subgroup of AML without 3q26 rearrangements, and is also associated with unfavorable outcomes (Barjesteh van Waalwijk van Doorn-Khosrovani et al., 2003; Valk et al., 2004; Lugthart et al., 2008) . In murine transplantation model of transformed leukemic cells, disruption of Evi-1 leads to significant loss of their proliferative activity . Thus, Evi-1 is a common and critical regulator essential for the proliferation of HSCs and leukemic cells.
Evi-1 contains two DNA-binding zinc finger domains (Perkins et al., 1991; Delwel et al., 1993) . Despite the presence of those DNA-binding domains, very few genes have been identified as direct targets of Evi-1 thus far. Gata2 is one of the critical targets for Evi-1 in the early hematopoietic development. Evi-1 was shown to bind directly to Gata2 promoter, and activate its transcription (Yuasa et al., 2005) . We earlier revealed candidate target genes of Evi-1 using gene expression profiling analysis in wild-type or Evi-1 À/À HSCs combined with the gene expression data of AML samples . Genes expressed in the para-aortic splanchnopleural (P-Sp) region of mouse embryos (Gata1, Gata2, and Angpt1), genes involved in the HSC regulation (Gata2, Angpt1, Mpl, Jag2, Pbx1, and Setbp1), and genes related to platelet formation (Gata1, Mpl, Itga2b, and Itgb3) were identified. Another group also provided set of genes as potential targets for Evi-1 regulation using an inducible EVI1-VP16 chimera, including Gadd45g, Gata2, and Klf5 (Yatsula et al., 2005) . Nevertheless, whether those are truly regulated by Evi-1 has yet to be determined.
Here, we have evaluated the potential effect of Evi-1 on Pbx1 transcription. Pbx1 is required for the maintenance of definitive hematopoiesis in the fetal liver (FL) and implicated in promoting hematopoietic progenitor cell expansion (DiMartino et al., 2001) . In contrast, Pbx1 is a regulator of HSC self-renewal that contributes to the maintenance of HSC quiescence (Ficara et al., 2008) . Thus, Pbx1 appears to act in a context-dependent manner within the hematopoietic system. In this report, to identify Evi-1 targets, we analyzed those candidate genes and found that Evi-1 binds to Pbx1 promoter and activates Pbx1 transcription. We also showed that RNAi-based knockdown of Pbx1 in Evi-1-transformed progenitors significantly reduced their colony-forming activity. These results indicate that Pbx1 is an important target of Evi-1 involved in Evi-1-mediated leukemogenesis.
Results
Pbx1 expression is transcriptionally regulated by Evi-1 In our earlier report , we identified candidate target genes of Evi-1 by comparing geneexpression profiles of wild-type and Evi-1 À/À adult HSCs. To narrow down the candidate targets, we first analyzed relative expression of several candidate genes in control-or Evi-1-transduced hematopoietic stem/ progenitors. Bone marrow progenitor (cKit þ ) cells were transduced with GFP or Evi-1-GFP-expressing retroviruses, and GFP þ cells were sorted ( Figure 1a ). The low mean intensity of GFP fluorescent is a characteristic feature of cells transduced with Evi-1-expressing retrovirus. Quantitative real-time PCR using the GFP þ cells revealed that Evi-1 increased the expression of Pbx1 (mean fold change; 2.50) (Figure 1b) . We then assessed the Pbx1 expression in wild-type and Evi-1-deficient FL cells because Evi-1 is required for HSC proliferation in FL . As shown in Figure 1c , the expression of Pbx1 is lower in Evi-1-deficient FL cells than that in wild-type FL cells. These results indicate that Pbx1 is a potential candidate gene activated by Evi-1.
To determine whether Evi-1 was directly involved in transcriptional regulation of Pbx1, we next performed luciferase reporter assay. As shown in Figure 1d , the luciferase activity of the Pbx1 reporter plasmid (Pbx1-FL), which includes 3.2 kb upstream of the translational initiation codon (TIC) of Pbx1, showed around two-fold increase over the promoter-less luciferase reporter pGL4.10 (pGL4-Vec). We next generated deletion constructs, and found that deletions ranging from À3.2 to À0.5 kb did not affect activation of the reporter constructs, whereas an internal deletion of the proximal 0.3 kb region completely abolished promoter activity. These results indicate that Pbx1 is a transcriptional target of Evi-1, and the TIC-proximal region (within À0.5 kb) of Pbx1 gene is necessary for EVI-1-mediated Pbx1 activation.
Identification of functional domains of Evi-1 responsible for Pbx1 expression As Evi-1 has several distinct domains with defined biochemical functions (Goyama and Kurokawa, 2009 ), we next analyzed transcriptional activities of a series of Evi-1 mutants that harbor deletion of the functional domains or substitution of specific residues (Figure 2a) . The first zinc-finger domain (1st-ZF) recognizes GA (T/C) AAGA (T/C) AAGATAA consensus sequences in vitro (Perkins et al., 1991; Delwel et al., 1993) , and is essential for repressing TGF-b signaling by binding to Smad3 (Kurokawa et al., 1998) . The 1st-ZF is also required for inhibiting JNK activity (Kurokawa et al., 2000) . The second zinc-finger domain (2nd-ZF) recognizes a consensus sequence of GAAGAT or GATGAG (Funabiki et al., 1994; Yuasa et al., 2005) , and is essential for AP-1 activation (Tanaka et al., 1994) . The region between amino acid 608 and 732 of Evi-1, which we call the repression domain, is required for the efficient repression of TGF-b signaling, although it does not contribute to binding to Smad3 (Kurokawa et al., 1998) . The region containing CtBP-binding-motif-like sequences, PLDLS at amino acid 584, is responsible for the interaction with CtBP1 (Izutsu et al., 2001) . In addition, Evi-1 contains a highly acidic domain at the C-terminus, which is required for Evi-1-mediated P-Sp hematopoiesis . Each construct was transfected into COS7 cells together with D-0.5 reporter construct. As shown in Figure 2a , the deletion including the latter half of the 1st-ZF (DZF5-7, DZF1-7) and the entire 2nd-ZF (DZF8-10, DZF8-10 þ AD) completely abolishes the reporter activity. Given that DZF5-7 and DZF8-10 still possess some biochemical functions, such as repression ability of TGF-b signaling (Kurokawa et al., 1998) , it is unlikely that the diminished reporter activity of these mutants is due to drastic changes in the tertiary and quaternary structures of the protein.
Earlier works have shown that Evi-1 binds directly to DNA through these zinc-finger domains (Perkins et al., 1991; Delwel et al., 1993; Funabiki et al., 1994; Yuasa et al., 2005) , we therefore asked whether Evi-1 requires direct sequence-specific DNA binding to induce Pbx1 expression. We found five possible binding sequences for the 1st-ZF (Sites 1, 2, 3, 4, and 6) and one sequences for the 2nd-ZF in this promoter region (Site 5) (Figure 2b) , and created promoter constructs that carried mutated Evi-1-binding sites. However, none of these mutations affected the luciferase activity, suggesting that Evi-1 does not require sequence-specific DNA binding to activate Pbx1 (Figure 2c ). We also assessed the effect of AP-1 signaling for Pbx1 activation since the 2nd-ZF is essential for AP-1 activation by Evi-1 (Tanaka et al., 1994) . The D-0.5 reporter vector was transfected into the COS7 cells together with expression vector c-Jun or AP-1 activator reagent, phorbol 12-myristate 13-acetate (PMA). However, neither c-Jun expression nor PMA addition activated Pbx1 transcription (data not shown). Thus, Evi-1 upregulates Pbx1 expression through both the first and second zinc-finger domains, but the detailed mechanisms underlying Evi-1-mediated Pbx1 activation remain to be elucidated.
EVI-1 binds to PBX1 promoter as a transcriptional regulator in human erythroblast leukemia cells To determine whether Evi-1 binds to the Pbx1 promoter in vivo, we performed a chromatin immunoprecipitation (ChIP) analysis using human erythroblast leukemia (HEL) cells that endogenously express EVI-1 protein.
We found that two alternatively spliced variants of Evi-1 activates Pbx1 transcription M Shimabe et al PBX1, PBX1A and PBX1B, were present in HEL cells, with PBX1B appearing as a predominant form (Figure 3a and c) . Knockdown of EVI-1 expression using transient transfection of shRNA (Liu et al., 2006) resulted in a significant decrease in PBX1 mRNA and proteins (both PBX1A and PBX1B) expression, suggest- The genomic region was amplified by quantitative realtime PCR using primers specific for À354 to À254 bp (À354/À254), À1076 to À960 bp (À1076/À960) and À11277 to À11113 bp (À11277/À11113) upstream regions of PBX1, respectively (Supplementary Table S1 ). GAPDH promoter region was also used as a control. Among different PBX1 promoter segments, a fragment containing the À354/À254 region, which is located in the homologous region of mouse Pbx1 promoter (D-0.5), bound most robustly to the EVI-1 protein.
In contrast, fragments containing À1076/À960 and À11277/À11113 regions were not amplified from the same DNA ( Figure 3d ). These results indicate that EVI-1 binds to PBX1 promoter as a transcriptional regulator.
Pbx1 is required for efficient propagation of Evi-1-transformed cells
To evaluate a role for Pbx1 in Evi-1-induced myeloid transformation, we first established colony-replating assay using Evi-1-expressing retrovirus. Bone marrow cells derived from 5-fluorouracil-treated mice were transduced with Evi-1, and were subjected to serialreplating assays with two sets of cytokine combinations ( Figure 4a ). Consistent with the earlier report (Laricchia-Robbio and Nucifora, 2008), primary bone marrow progenitors transduced with the empty vector matured and ceased proliferation after repeated replating in a semisolid medium, whereas those transduced with Evi-1 formed colonies through at least six rounds of plating ( Figure 4b ). Wright-Giemsa-stained cytospin preparation of the cells after three rounds of plating showed that the control cells appeared differentiated, and only macrophages were observed. In contrast, the Evi-1-transduced colonies were composed of myeloblasts and immature myeloid cells with dysplasia ( Figure 4c ). Interestingly, the frequency of GFP þ cells in the Evi-1-infected groups decreased after first plating, suggesting that high-level expression of Evi-1 attenuates the proliferating capacity of bone marrow cells. However, the GFP-low cells, which express Evi-1 at low level, gradually increased and constituted over 80% after three rounds of plating (Figure 4d and e). These results suggest that the relatively low level of expression of Evi-1 confers sustained colony-forming activity in bone marrow cells.
Next, we transduced Pbx1-shRNA or control-shRNA into Evi-1-transduced progenitors after three rounds of plating, and assessed their colony-forming activity (Figure 5a ). The inhibitory effect of shRNA on Pbx1 expression was confirmed using NIH3T3 cells (Figure 5b ). Of note, RNAi-based knockdown of Pbx1 in Evi-1-transduced progenitors significantly reduced their colonyforming activity (Figure 5c ). We then assessed the effect of Pbx1 knockdown in bone marrow progenitors transduced by E2A/HLF or AML1/ETO chimeric genes generated in t(17;19) or t(8;21), respectively. These chimeric genes are also known to transform murine bone marrow cells (Smith et al., 2002; Takeshita et al., 2008) , and were used as controls. As shown in Figure 5d , knockdown of Pbx1 did not impair bone marrow transformation by E2A/HLF or AML1/ETO. These results indicate that Pbx1 is specifically, as opposed to generally, required for the maintenance of transformation mediated by Evi-1.
PBX1 expression is correlated with EVI-1 expression in AML leukemic cells
Finally, we closely investigated the expression of EVI-1 and PBX1 in AML leukemic cells. First, we analyzed gene expression data of leukemic cells of 285 individuals with AML (Valk et al., 2004) . As there are two probes (221884_at and 215851_at) for EVI-1 expression and four probes (205253_at, 212148_at, 212151_at and 217617_at) for PBX1 expression, the correlation between expression of EVI-1 and PBX1 was assessed using these probes. Remarkably, we constantly found positive correlations between one of the EVI-1 probes (221884_at) and the PBX1 probes ( Table 1) , suggesting that the expression of PBX1 positively correlates with that of EVI-1. Next, we independently examined the levels of EVI-1 and PBX1 expression in bone marrow cells of 33 cases with human AML in our institute (Supplementary Table S3 ) using quantitative realtime PCR analysis. Again, we found a tendency for positive correlation between EVI-1 and PBX1 levels (Pearson's product-moment correlation coefficient ¼ 0.293 (P ¼ 0.098)) (Supplementary Figure S1 ). These data Evi-1 activates Pbx1 transcription M Shimabe et al suggest that the correlation between EVI-1 and PBX1 exists in human AML.
Discussion
Despite the established role of Evi-1 in leukemia development, molecular mechanisms underlying Evi-1-mediated leukemogenesis remain elusive. Especially, very few genes have been identified as downstream targets of Evi-1 thus far. In this study, we report a novel Evi-1-regulated gene, Pbx1. Several approaches were used to show that Pbx1 is a target of Evi-1. First, we combined gene-expression-profiling analysis in wild-type or Evi-1 À/À HSCs with the gene-expression data of AML samples, and found that the expression of Pbx1 
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correlates with that of Evi-1 in both HSCs and AML cells . Analysis of gene expression data of 285 individuals with AML (Valk et al., 2004) showed the positive correlation between EVI-1 and PBX1 expression. Our independent examination also showed a tendency toward positive correlation, although, it did not reach statistical significance probably due to the limited sample size (n ¼ 33). In addition, we showed that Pbx1 expression is increased by Evi-1 overexpression and is decreased in Evi-1
Second, through an extensive Pbx1 promoter analysis, we showed that Evi-1 regulates the Pbx1 transcription by binding to the proximal region just upstream of the Pbx1 TIC. Furthermore, our functional assay revealed that RNAi-based knockdown of Pbx1 significantly inhibited Evi-1-induced colony-forming activity, whereas knockdown of Pbx1 did not impair bone marrow transformation by E2A/HLF or AML1/ETO. These results indicate that Pbx1 is one of the authentic targets of Evi-1 in both hematopoietic stem/progenitors and leukemic cells.
How Evi-1 achieves activation of Pbx1 remains to be determined. Although both the 1st-ZF and the 2nd-ZF of Evi-1 are required for Pbx1 activation, mutating the putative consensus-binding sites did not lead to reduction of the reporter activities. The ChIP analysis, however, showed that EVI-1 forms a complex on the promoter region of PBX1 that is indispensable with Evi-1-mediated upregulation of Pbx1. One possibility is that Evi-1 may bind to Pbx1 promoter sequence that is different from the known consensus sequence. Otherwise, Evi-1 may form a complex with other transcriptional factors that directly bind to the region of Pbx1 promoter.
Pbx1 is a TALE class homeodomain transcription factor that critically regulates numerous embryonic processes, including morphologic patterning, organogenesis, and hematopoiesis (DiMartino et al., 2001; Selleri et al., 2001; Kim et al., 2002; Schnabel et al., 2003; Manley et al., 2004) . It enhances the relatively nonspecific DNA-binding properties of Hox transcription factors and regulates gene expression as heterooligomeric complexes with Hox proteins (Mann, 1995) . It acts as a protein partner to facilitate cooperative DNA binding by Hox proteins (Lawrence et al., 1996) . Recently, it was reported that Pbx1 controls self-renewal of HSCs (Ficara et al., 2008) , suggesting that Pbx1 may mediate the function of Evi-1 in the regulation of HSCs. On the other hand, we found that enforced expression of Pbx1 alone was not sufficient to restore the decreased colony-forming capacity of Evi-1 À/À P-Sp cells (data not shown). These Pbx1 has also been implicated in the development of several tumors including hematological malignancies (Kamps et al., 1990 (Kamps et al., , 1991 Nourse et al., 1990; Qiu et al., Shiraishi et al., 2007; Park et al., 2008) . It is required for the execution of some Hox-dependent block of differentiation, and/or transformation (Krosl et al., 1998; Knoepfler et al., 2001; Yaron et al., 2001) , and mutations of HoxA9 that prevent interaction with Pbx proteins abrogate its oncogenic properties (Schnabel et al., 2000) . Notably, Evi-1 also cooperates with Hoxa and Meis1 in myeloid leukemogenesis (Jin et al., 2007) . Therefore, together with the findings in this report, the Evi-1-Pbx1 pathway may cooperate with Hox proteins for leukemia development. In summary, we showed that Evi-1 binds to the Pbx1 promoter and activates its expression. Aberrant expression of Pbx1 is responsible, at least in part, for the leukemogenic activity of Evi-1. Given that both Evi-1 and Pbx1 are highly expressed in a variety of tumors, the role of the Evi-1-Pbx1 pathway may have an important function for cancer development in a broad spectrum of tissues.
Materials and methods

DNA constructs
The plasmid pME18S-EVI-1 (human) (Tanaka et al., 1994; Nitta et al., 2005) , various EVI-1 mutants inserted in pME18S (Tanaka et al., 1994; Kurokawa et al., 1998; Izutsu et al., 2001) , pMXs-neo-E2A/HLF (a gift from T Inaba), FLAGtagged-AML1/ETO (a gift from SW Hiebert) (Meyers et al., 1993) inserted in pMSCV-neo (Clontech, Mountain view, CA, USA) , have been described earlier.
Mouse Evi-1 cDNA was obtained using the mRNA prepared from P-Sp region of the embryo, and inserted into the pGCDNsam-IRES-eGFP retroviral vector (a gift from H Nakauchi and M Onodera). The plasmid pMYs-mouse Evi-1-IG has been described earlier (Watanabe-Okochi et al., 2008) .
Retroviral transduction
To obtain retrovirus supernatants, 8 Â 10 5 Plat-E packaging cells per 6-cm culture dish were transiently transfected with 3 mg of each retrovirus vector, mixed with 9 mL of FuGENE 6 (Roche, Indianapolis, IN, USA), and incubated. Supernatant containing retrovirus was collected 48 h after transfection, filtered using 0.45-mm filters and used immediately for infection. Retroviral transduction to bone marrow progenitors was performed as described earlier . Bone marrow mononuclear cells were isolated by centrifugation using Histopaque 1083 (Sigma, St Louis, MO, USA), from femora and tibiae of wild-type (WT) C57Bl/6 mice treated with 5-fluorouracil (150 mg/head) 4 days before harvest. The cell suspension was cultured for overnight in a prestimulation medium (alpha-Minimum Essential Medium supplemented with 20% of FCS, 50 ng/ml of stem cell factor (SCF; Wako, Osaka, Japan), Flt3-ligand (Flt3 L; R&D, Minneapolis, MN, USA), thrombopoietin and a fusion protein of IL-6R and IL-6). After stimulation, cells were harvested and seeded with retroviral supernatants on RetroNectin (Takara Bio, Otsu, Japan) coated dishes.
Quantitative real-time PCR analysis cKit þ bone marrow mononuclear cells were isolated with anti-CD177 (cKit) magnetic beads and using the AutoMACS apparatus (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. pGCDNsammouse Evi-1-IRES-eGFP or pGCDNsam-IRES-eGFP retrovirus was introduced into cKit þ bone marrow progenitors. Total RNA was extracted from the GFP þ bone marrow progenitors sorted by a FACSAria cell sorter (BD Biosciences, San Jose, CA, USA), FL cells and HEL cells using RNeasy Mini kit (Qiagen, Hilden, Germany). Reverse transcription was performed using SuperScript III (Invitrogen, Carlsbad, CA, USA). For quantitative real-time PCR, we used Taqman or SYBR Green assays. A list of primers and Taqman probes is provided in Supplementary Table S1. All reactions were performed using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) or LC480 (Roche) according to the manufacturer's instructions. Amplification of GAPDH or ACTB cDNA was used as the endogenous normalization standard.
Reporter gene constructs and luciferase reporter assay 5 0 upstream region of mouse Pbx1 (À3247 to À179 bp) was isolated from BAC clone (RP24-243I12) by PCR amplification. The specific primers are listed in Supplementary Table S1 . PCR products were directly subcoloned into the pGL4.10 reporter vector (Promega, Madison, WI, USA), named Pbx1-FL. D-1.2 reporter plasmid was generated by restriction digestion of Pbx1-FL using BamH1 and EcoRV. The other reporter plasmids (D-0.7, D-0.6, D-0.5, and 3 0 delta) were amplified by PCR. Mutations of the Evi-1 recognition sites in D-0.5 construct were introduced by QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) using the primers shown in Supplementary Table S2. All constructs were verified by DNA sequencing.
For analysis of luciferase activities, COS7 cells were seeded in 12-well culture plates at a density of 2 Â 10 4 per well. At 12 h after seeding, the cells were transfected with 200 ng of each luciferase reporter construct, together with 200 ng of each appropriate expression plasmid (for example pME18S vector (Mock), pME18S-EVI-1) using FuGENE 6 (Roche). The cells were harvested 48 h after transfection and assayed. Firefly luciferase activity was measured as relative light units. The relative light units from individual transfection were normalized by measurement of Renilla luciferase activity in the same samples. Results are expressed as fold activation and standard deviations (s.d.) from all these measurements. Fold activation was expressed as the ratio of normalized luciferase activity with EVI-1 expression to that without EVI-1 expression. Evi-1 activates Pbx1 transcription M Shimabe et al
ChIP assay
A ChIP analysis was performed as described earlier (Lee et al., 2006) , with minor modifications. Briefly, HEL cells (1-5 Â 10 7 ) were crosslinked with 1% formaldehyde. Subsequently chromatin was fragmented by sonication to obtain an average fragment length of 200-900 bp (Bronson Sonifier 250). After the chromatin fraction was incubated with Normal Rabbit IgG (Abcam Inc., Cambridge, MA, USA) or anti-EVI-1 antibody (#C50E12; Cell Signaling Technology, Danvers, MA, USA), immune complexes were bound to Dynabeads protein G (Invitrogen). Eluted DNA samples were then analyzed by quantitative real-time PCR using specific primer pairs (Lim et al., 2005) in Supplementary Table S1 . PCR results were calculated validly using the DDCt method.
Myeloid progenitor transformation assay
Myeloid progenitor transformation assay was performed as described earlier with minor modifications. In brief, bone marrow progenitors infected with pGCDNsam-mouse Evi-1-IRES-eGFP retrovirus, pMYsmouse Evi-1 IG retrovirus or respective control retrovirus were cultured in Methocult M3434 or M3134 (Stem Cell Technologies, Vancouver, BC Canada) containing 50 ng/ml mSCF, 10 ng/ml mIL-3, 10 ng/ml hIL-6, 10 ng/ml GM-CSF, with or without 3 unit/ml EPO, at a density of 1 Â 10 4 cells per 35-mm plate. Colony scoring and replating were repeated weekly. Transformed cells from the third to fifth round of in vitro plating were subsequently infected with retrovirus encoding either Pbx1-shRNA, or control-shRNA using RetroNectin in prestimulation medium supplemented with 10% WEHI conditioned medium. The cells were replated at 1 Â 10 5 per plate in M3434 in the presence of 1 mg/ml puromycin. Puromycin-resistant colonies were then replated under identical conditions.
Clinical samples
To elucidate the level of PBX1 expression in clinical samples, we used gene expression data of 285 individuals with AML (www.ncbi.nlm.gov/geo, accession number GSE1159 [NCBI GEO]) (Valk et al., 2004) . Normalization and expression values of the microarray data were calculated using the statistical language R (http://www.bioconductor.org).
We independently analyzed bone marrow samples from 33 AML patients (Supplementary Table S3 ) after obtaining written informed consent. Studies involving human subjects were done in accordance with the ethical guidelines for biomedical research involving human subjects, which was developed by the Ministry of Health, Labour and Welfare, Japan, the Ministry of Education, Culture, Sports, Science, and Technology, Japan, and the Ministry of Economy, Trade, and Industry, Japan, and enforced 24 on March 29, 2001. Procedures were approved by ethical committee of Tokyo University. The expression of EVI-1 (Primer; EVI-1 SYBR), PBX1 and ACTB were measured using quantitative real-time PCR techniques. The specific primers are listed in Supplementary Table S1 .
Statistical analysis
Statistical significance of differences between parameters was assessed using a two-tailed paired t test. The correlation between EVI-1 expression and PBX1 expression was estimated using the Pearson's product-moment correlation coefficient. 
